TY  - JOUR
AU  - Napp, Adriane E.
AU  - Haase, Robert
AU  - Laule, Michael
AU  - Schuetz, Georg M.
AU  - Rief, Matthias
AU  - Dreger, Henryk
AU  - Feuchtner, Gudrun
AU  - Friedrich, Guy
AU  - Spacek, Miloslav
AU  - Suchanek, Vojtech
AU  - Kofoed, Klaus Fuglsang
AU  - Engstroem, Thomas
AU  - Schroeder, Stephen
AU  - Drosch, Tanja
AU  - Gutberlet, Matthias
AU  - Woinke, Michael
AU  - Maurovich-Horvat, Pal
AU  - Merkely, Bela
AU  - Donnelly, Patrick
AU  - Ball, Peter
AU  - Dodd, Jonathan D.
AU  - Quinn, Martin
AU  - Saba, Luca
AU  - Porcu, Maurizio
AU  - Francone, Marco
AU  - Mancone, Massimo
AU  - Erglis, Andrejs
AU  - Zvaigzne, Ligita
AU  - Jankauskas, Antanas
AU  - Sakalyte, Gintare
AU  - Haran, Tomasz
AU  - Ilnicka-Suckiel, Malgorzata
AU  - Bettencourt, Nuno
AU  - Gama-Ribeiro, Vasco
AU  - Condrea, Sebastian
AU  - Benedek, Imre
AU  - Adjic, Nada Cemerlic
AU  - Adjic, Oto
AU  - Rodriguez-Palomares, Jose
AU  - del Blanco, Bruno Garcia
AU  - Roditi, Giles
AU  - Berry, Colin
AU  - Davis, Gershan
AU  - Thwaite, Erica
AU  - Knuuti, Juhani
AU  - Pietila, Mikko
AU  - Kepka, Cezary
AU  - Kruk, Mariusz
AU  - Vidakovic, Radosav
AU  - Neskovic, Aleksandar N.
AU  - Diez, Ignacio
AU  - Lecumberri, Inigo
AU  - Geleijns, Jacob
AU  - Kubiak, Christine
AU  - Strenge-Hesse, Anke
AU  - Do, The-Hoang
AU  - Fromel, Felix
AU  - Gutierrez-Ibarluzea, Inaki
AU  - Benguria-Arrate, Gaizka
AU  - Keiding, Hans
AU  - Katzer, Christoph
AU  - Mueller-Nordhorn, Jacqueline
AU  - Rieckmann, Nina
AU  - Walther, Mario
AU  - Schlattmann, Peter
AU  - Dewey, Marc
AU  - DISCHARGE Trial Grp
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1603
AB  - More than 3.5 million invasive coronary angiographies (ICA) are performed in Europe annually. Approximately 2 million of these invasive procedures might be reduced by noninvasive tests because no coronary intervention is performed. Computed tomography (CT) is the most accurate noninvasive test for detection and exclusion of coronary artery disease (CAD). To investigate the comparative effectiveness of CT and ICA, we designed the European pragmatic multicentre DISCHARGE trial funded by the 7th Framework Programme of the European Union (EC-GA 603266). In this trial, patients with a low-to-intermediate pretest probability (10-60 %) of suspected CAD and a clinical indication for ICA because of stable chest pain will be randomised in a 1-to-1 ratio to CT or ICA. CT and ICA findings guide subsequent management decisions by the local heart teams according to current evidence and European guidelines. Major adverse cardiovascular events (MACE) defined as cardiovascular death, myocardial infarction and stroke as a composite endpoint will be the primary outcome measure. Secondary and other outcomes include cost-effectiveness, radiation exposure, health-related quality of life (HRQoL), socioeconomic status, lifestyle, adverse events related to CT/ICA, and gender differences. The DISCHARGE trial will assess the comparative effectiveness of CT and ICA. aEuro cent Coronary artery disease (CAD) is a major cause of morbidity and mortality. aEuro cent Invasive coronary angiography (ICA) is the reference standard for detection of CAD. aEuro cent Noninvasive computed tomography angiography excludes CAD with high sensitivity. aEuro cent CT may effectively reduce the approximately 2 million negative ICAs in Europe. aEuro cent DISCHARGE addresses this hypothesis in patients with low-to-intermediate pretest probability for CAD.
T2  - European Radiology
T1  - Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial
VL  - 27
IS  - 7
SP  - 2957
EP  - 2968
DO  - 10.1007/s00330-016-4620-z
ER  - 

@article{
author = "Napp, Adriane E. and Haase, Robert and Laule, Michael and Schuetz, Georg M. and Rief, Matthias and Dreger, Henryk and Feuchtner, Gudrun and Friedrich, Guy and Spacek, Miloslav and Suchanek, Vojtech and Kofoed, Klaus Fuglsang and Engstroem, Thomas and Schroeder, Stephen and Drosch, Tanja and Gutberlet, Matthias and Woinke, Michael and Maurovich-Horvat, Pal and Merkely, Bela and Donnelly, Patrick and Ball, Peter and Dodd, Jonathan D. and Quinn, Martin and Saba, Luca and Porcu, Maurizio and Francone, Marco and Mancone, Massimo and Erglis, Andrejs and Zvaigzne, Ligita and Jankauskas, Antanas and Sakalyte, Gintare and Haran, Tomasz and Ilnicka-Suckiel, Malgorzata and Bettencourt, Nuno and Gama-Ribeiro, Vasco and Condrea, Sebastian and Benedek, Imre and Adjic, Nada Cemerlic and Adjic, Oto and Rodriguez-Palomares, Jose and del Blanco, Bruno Garcia and Roditi, Giles and Berry, Colin and Davis, Gershan and Thwaite, Erica and Knuuti, Juhani and Pietila, Mikko and Kepka, Cezary and Kruk, Mariusz and Vidakovic, Radosav and Neskovic, Aleksandar N. and Diez, Ignacio and Lecumberri, Inigo and Geleijns, Jacob and Kubiak, Christine and Strenge-Hesse, Anke and Do, The-Hoang and Fromel, Felix and Gutierrez-Ibarluzea, Inaki and Benguria-Arrate, Gaizka and Keiding, Hans and Katzer, Christoph and Mueller-Nordhorn, Jacqueline and Rieckmann, Nina and Walther, Mario and Schlattmann, Peter and Dewey, Marc and DISCHARGE Trial Grp",
year = "2017",
abstract = "More than 3.5 million invasive coronary angiographies (ICA) are performed in Europe annually. Approximately 2 million of these invasive procedures might be reduced by noninvasive tests because no coronary intervention is performed. Computed tomography (CT) is the most accurate noninvasive test for detection and exclusion of coronary artery disease (CAD). To investigate the comparative effectiveness of CT and ICA, we designed the European pragmatic multicentre DISCHARGE trial funded by the 7th Framework Programme of the European Union (EC-GA 603266). In this trial, patients with a low-to-intermediate pretest probability (10-60 %) of suspected CAD and a clinical indication for ICA because of stable chest pain will be randomised in a 1-to-1 ratio to CT or ICA. CT and ICA findings guide subsequent management decisions by the local heart teams according to current evidence and European guidelines. Major adverse cardiovascular events (MACE) defined as cardiovascular death, myocardial infarction and stroke as a composite endpoint will be the primary outcome measure. Secondary and other outcomes include cost-effectiveness, radiation exposure, health-related quality of life (HRQoL), socioeconomic status, lifestyle, adverse events related to CT/ICA, and gender differences. The DISCHARGE trial will assess the comparative effectiveness of CT and ICA. aEuro cent Coronary artery disease (CAD) is a major cause of morbidity and mortality. aEuro cent Invasive coronary angiography (ICA) is the reference standard for detection of CAD. aEuro cent Noninvasive computed tomography angiography excludes CAD with high sensitivity. aEuro cent CT may effectively reduce the approximately 2 million negative ICAs in Europe. aEuro cent DISCHARGE addresses this hypothesis in patients with low-to-intermediate pretest probability for CAD.",
journal = "European Radiology",
title = "Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial",
volume = "27",
number = "7",
pages = "2957-2968",
doi = "10.1007/s00330-016-4620-z"
}

Napp, A. E., Haase, R., Laule, M., Schuetz, G. M., Rief, M., Dreger, H., Feuchtner, G., Friedrich, G., Spacek, M., Suchanek, V., Kofoed, K. F., Engstroem, T., Schroeder, S., Drosch, T., Gutberlet, M., Woinke, M., Maurovich-Horvat, P., Merkely, B., Donnelly, P., Ball, P., Dodd, J. D., Quinn, M., Saba, L., Porcu, M., Francone, M., Mancone, M., Erglis, A., Zvaigzne, L., Jankauskas, A., Sakalyte, G., Haran, T., Ilnicka-Suckiel, M., Bettencourt, N., Gama-Ribeiro, V., Condrea, S., Benedek, I., Adjic, N. C., Adjic, O., Rodriguez-Palomares, J., del Blanco, B. G., Roditi, G., Berry, C., Davis, G., Thwaite, E., Knuuti, J., Pietila, M., Kepka, C., Kruk, M., Vidakovic, R., Neskovic, A. N., Diez, I., Lecumberri, I., Geleijns, J., Kubiak, C., Strenge-Hesse, A., Do, T., Fromel, F., Gutierrez-Ibarluzea, I., Benguria-Arrate, G., Keiding, H., Katzer, C., Mueller-Nordhorn, J., Rieckmann, N., Walther, M., Schlattmann, P., Dewey, M.,& DISCHARGE Trial Grp. (2017). Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. in European Radiology, 27(7), 2957-2968.
https://doi.org/10.1007/s00330-016-4620-z

Napp AE, Haase R, Laule M, Schuetz GM, Rief M, Dreger H, Feuchtner G, Friedrich G, Spacek M, Suchanek V, Kofoed KF, Engstroem T, Schroeder S, Drosch T, Gutberlet M, Woinke M, Maurovich-Horvat P, Merkely B, Donnelly P, Ball P, Dodd JD, Quinn M, Saba L, Porcu M, Francone M, Mancone M, Erglis A, Zvaigzne L, Jankauskas A, Sakalyte G, Haran T, Ilnicka-Suckiel M, Bettencourt N, Gama-Ribeiro V, Condrea S, Benedek I, Adjic NC, Adjic O, Rodriguez-Palomares J, del Blanco BG, Roditi G, Berry C, Davis G, Thwaite E, Knuuti J, Pietila M, Kepka C, Kruk M, Vidakovic R, Neskovic AN, Diez I, Lecumberri I, Geleijns J, Kubiak C, Strenge-Hesse A, Do T, Fromel F, Gutierrez-Ibarluzea I, Benguria-Arrate G, Keiding H, Katzer C, Mueller-Nordhorn J, Rieckmann N, Walther M, Schlattmann P, Dewey M, DISCHARGE Trial Grp. Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. in European Radiology. 2017;27(7):2957-2968.
doi:10.1007/s00330-016-4620-z .

Napp, Adriane E., Haase, Robert, Laule, Michael, Schuetz, Georg M., Rief, Matthias, Dreger, Henryk, Feuchtner, Gudrun, Friedrich, Guy, Spacek, Miloslav, Suchanek, Vojtech, Kofoed, Klaus Fuglsang, Engstroem, Thomas, Schroeder, Stephen, Drosch, Tanja, Gutberlet, Matthias, Woinke, Michael, Maurovich-Horvat, Pal, Merkely, Bela, Donnelly, Patrick, Ball, Peter, Dodd, Jonathan D., Quinn, Martin, Saba, Luca, Porcu, Maurizio, Francone, Marco, Mancone, Massimo, Erglis, Andrejs, Zvaigzne, Ligita, Jankauskas, Antanas, Sakalyte, Gintare, Haran, Tomasz, Ilnicka-Suckiel, Malgorzata, Bettencourt, Nuno, Gama-Ribeiro, Vasco, Condrea, Sebastian, Benedek, Imre, Adjic, Nada Cemerlic, Adjic, Oto, Rodriguez-Palomares, Jose, del Blanco, Bruno Garcia, Roditi, Giles, Berry, Colin, Davis, Gershan, Thwaite, Erica, Knuuti, Juhani, Pietila, Mikko, Kepka, Cezary, Kruk, Mariusz, Vidakovic, Radosav, Neskovic, Aleksandar N., Diez, Ignacio, Lecumberri, Inigo, Geleijns, Jacob, Kubiak, Christine, Strenge-Hesse, Anke, Do, The-Hoang, Fromel, Felix, Gutierrez-Ibarluzea, Inaki, Benguria-Arrate, Gaizka, Keiding, Hans, Katzer, Christoph, Mueller-Nordhorn, Jacqueline, Rieckmann, Nina, Walther, Mario, Schlattmann, Peter, Dewey, Marc, DISCHARGE Trial Grp, "Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial" in European Radiology, 27, no. 7 (2017):2957-2968,
https://doi.org/10.1007/s00330-016-4620-z . .

TY  - JOUR
AU  - Sadowski, Jerzy
AU  - Bartus, Krzysztof
AU  - Kapelak, Boguslaw
AU  - Rocha-Singh, Krishna J.
AU  - Katholi, Richard E.
AU  - Witkowski, Adam
AU  - Kadziela, Jacek
AU  - Januszewicz, Andrzej
AU  - Prejbisz, Aleksander
AU  - Walton, Anthony S.
AU  - Sievert, Horst
AU  - Id, Dani
AU  - Wunderlich, Nina
AU  - Whitbourn, Robert
AU  - Rump, Lars Christian
AU  - Vonend, Oliver
AU  - Saleh, Andreas
AU  - Thambar, Suku
AU  - Nanra, Ranjit
AU  - Zeller, Thomas
AU  - Erglis, Andrejs
AU  - Sagic, Dragan
AU  - Bošković, Srdjan
AU  - Brachmann, Johannes
AU  - Schmidt, Martin
AU  - Wenzel, Ulrich O.
AU  - Bart, Bradley A.
AU  - Schmieder, Roland E.
AU  - Scheinert, Dierk
AU  - Boergel, Jan
AU  - Straley, Craig
AU  - Symplicity HTN-1 Investigators
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4283
AB  - Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)
T2  - Hypertension
T1  - Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months
VL  - 57
IS  - 5
SP  - 911
EP  - 917
DO  - 10.1161/HYPERTENSIONAHA.110.163014
ER  - 

@article{
author = "Sadowski, Jerzy and Bartus, Krzysztof and Kapelak, Boguslaw and Rocha-Singh, Krishna J. and Katholi, Richard E. and Witkowski, Adam and Kadziela, Jacek and Januszewicz, Andrzej and Prejbisz, Aleksander and Walton, Anthony S. and Sievert, Horst and Id, Dani and Wunderlich, Nina and Whitbourn, Robert and Rump, Lars Christian and Vonend, Oliver and Saleh, Andreas and Thambar, Suku and Nanra, Ranjit and Zeller, Thomas and Erglis, Andrejs and Sagic, Dragan and Bošković, Srdjan and Brachmann, Johannes and Schmidt, Martin and Wenzel, Ulrich O. and Bart, Bradley A. and Schmieder, Roland E. and Scheinert, Dierk and Boergel, Jan and Straley, Craig and Symplicity HTN-1 Investigators",
year = "2011",
abstract = "Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)",
journal = "Hypertension",
title = "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months",
volume = "57",
number = "5",
pages = "911-917",
doi = "10.1161/HYPERTENSIONAHA.110.163014"
}

Sadowski, J., Bartus, K., Kapelak, B., Rocha-Singh, K. J., Katholi, R. E., Witkowski, A., Kadziela, J., Januszewicz, A., Prejbisz, A., Walton, A. S., Sievert, H., Id, D., Wunderlich, N., Whitbourn, R., Rump, L. C., Vonend, O., Saleh, A., Thambar, S., Nanra, R., Zeller, T., Erglis, A., Sagic, D., Bošković, S., Brachmann, J., Schmidt, M., Wenzel, U. O., Bart, B. A., Schmieder, R. E., Scheinert, D., Boergel, J., Straley, C.,& Symplicity HTN-1 Investigators. (2011). Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension, 57(5), 911-917.
https://doi.org/10.1161/HYPERTENSIONAHA.110.163014

Sadowski J, Bartus K, Kapelak B, Rocha-Singh KJ, Katholi RE, Witkowski A, Kadziela J, Januszewicz A, Prejbisz A, Walton AS, Sievert H, Id D, Wunderlich N, Whitbourn R, Rump LC, Vonend O, Saleh A, Thambar S, Nanra R, Zeller T, Erglis A, Sagic D, Bošković S, Brachmann J, Schmidt M, Wenzel UO, Bart BA, Schmieder RE, Scheinert D, Boergel J, Straley C, Symplicity HTN-1 Investigators. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension. 2011;57(5):911-917.
doi:10.1161/HYPERTENSIONAHA.110.163014 .

Sadowski, Jerzy, Bartus, Krzysztof, Kapelak, Boguslaw, Rocha-Singh, Krishna J., Katholi, Richard E., Witkowski, Adam, Kadziela, Jacek, Januszewicz, Andrzej, Prejbisz, Aleksander, Walton, Anthony S., Sievert, Horst, Id, Dani, Wunderlich, Nina, Whitbourn, Robert, Rump, Lars Christian, Vonend, Oliver, Saleh, Andreas, Thambar, Suku, Nanra, Ranjit, Zeller, Thomas, Erglis, Andrejs, Sagic, Dragan, Bošković, Srdjan, Brachmann, Johannes, Schmidt, Martin, Wenzel, Ulrich O., Bart, Bradley A., Schmieder, Roland E., Scheinert, Dierk, Boergel, Jan, Straley, Craig, Symplicity HTN-1 Investigators, "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months" in Hypertension, 57, no. 5 (2011):911-917,
https://doi.org/10.1161/HYPERTENSIONAHA.110.163014 . .